Secondary analysis of the phase 3 CANOPY and a phase 1 trial: pemivibart raised day-28 measured neutralising antibody titres against XBB.1.5 over 55-fold in adults with and without significant immunocompromise; calculated titres correlated with measured ones (Spearman ≥0.73).
Secondary analysis
Narayan et al. Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19